Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04880109 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
A Phase 2 study, sponsored by Aptabio Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT04880109 is a Phase 2 study that was terminated before completion, run by Aptabio Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT04880109, a Phase 2 study, was terminated before completion, sponsored by Aptabio Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19. It is anticipated that approximately 80 patients will be randomized into the study in a 1:1 ratio to 100 mg APX-115 or placebo arm.
Interventions
- DRUG Placebo
- DRUG APX-115
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-10-20 |
| Est. Completion | 2022-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04880109
The ClinicalTrials.gov registry entry for NCT04880109 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptabio Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04880109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04880109 about?
NCT04880109 is a clinical study titled "A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.". This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19. It is anticipated that approximately 80 patients will be randomized into the study i...
What is the current status of trial NCT04880109?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2021-10-20. Estimated completion is 2022-04-28.
What interventions are being tested in trial NCT04880109?
The interventions under investigation include: Placebo (DRUG), APX-115 (DRUG).
Who is sponsoring clinical trial NCT04880109?
This trial is sponsored by Aptabio Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.